Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05567783 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A
A Phase 2 study, sponsored by Vir Biotechnology.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2,977
- Enrollment target
NCT05567783 is a Phase 2 study that was terminated before completion, run by Vir Biotechnology. The registered enrollment target is 2,977 participants.
The verdict
NCT05567783, a Phase 2 study, was terminated before completion, sponsored by Vir Biotechnology.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2,977 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of VIR-2482 compared to placebo in preventing influenza A illness in healthy adults 18 to \<65 years of age without pre-existing risk factors for serious complications from influenza infection.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL VIR-2482 (450 mg)
- BIOLOGICAL VIR-2482 (1200 mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,977 participants |
| Start Date | 2022-10-30 |
| Est. Completion | 2023-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05567783
The ClinicalTrials.gov registry entry for NCT05567783 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2,977 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vir Biotechnology, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05567783 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05567783 about?
NCT05567783 is a clinical study titled "A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A". The purpose of this study is to evaluate the efficacy, safety, and tolerability of VIR-2482 compared to placebo in preventing influenza A illness in healthy adults 18 to \<65 years of age without pre-existing risk factors for serious complications from influenza infection.
What is the current status of trial NCT05567783?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2,977 participants. The study started on 2022-10-30. Estimated completion is 2023-08-31.
What interventions are being tested in trial NCT05567783?
The interventions under investigation include: Placebo (BIOLOGICAL), VIR-2482 (450 mg) (BIOLOGICAL), VIR-2482 (1200 mg) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05567783?
This trial is sponsored by Vir Biotechnology, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.